The integration of artificial intelligence (AI) into healthcare systems marked a pivotal evolution in clinical analytics architectures and governance structures, transforming data-driven decision-making from siloed, retrospective analyses to dynamic, predictive, and integrated frameworks. This period witnessed rapid advancements in machine learning (ML) applications for healthcare infrastructure, encompassing electronic health records (EHRs), imaging diagnostics, population health management, and real-time monitoring systems. Key developments included the shift toward federated learning to address data privacy concerns, the emergence of explainable AI (XAI) to enhance clinical trustworthiness, and the standardization of regulatory pathways for AI as medical devices. Architecturally, healthcare systems evolved from static analytics pipelines—where data ingestion, model training, and inference occurred in isolated phases—to adaptive, closed-loop configurations that incorporate feedback mechanisms for continuous model refinement and human-AI collaboration. Governance structures are adapted accordingly, emphasizing ethical frameworks to mitigate bias, ensure data equity, and promote algorithmic accountability, particularly for underserved populations. This review synthesizes literature from this timeframe, highlighting how AI-enabled analytics architectures facilitated precision medicine by integrating multimodal data sources, such as genomics, wearables, and social determinants of health, into cohesive systems. Challenges in interoperability and scalability were addressed through consensus guidelines like CONSORT-AI and SPIRIT-AI, which promoted transparent reporting of AI interventions in clinical trials. Moreover, the COVID-19 pandemic accelerated AI deployment in pandemic response systems, underscoring the need for resilient architectures capable of handling real-time data surges and uncertainty communication. Governance evolved to include multi-stakeholder perspectives, from regulatory bodies such as the FDA to clinical practitioners, ensuring that AI tools align with evidence-based medicine. This narrative review provides an original systems-level framing, organizing the literature around data-to-decision cycles, infrastructural integration, and governance maturation. By examining cross-study insights, it reveals how AI has fostered intelligent healthcare ecosystems, reducing diagnostic bias across diverse cohorts and enhancing decision support without over-relying on black-box models. Ultimately, this synthesis underscores the transition from AI as a supplementary tool to a foundational element of healthcare systems, paving the way for equitable, efficient clinical analytics.
Sepsis remains a major cause of mortality in intensive care units worldwide, with an estimated 49 million cases and over 11 million deaths annually, highlighting the need for earlier detection to improve outcomes. This systematic review synthesizes evidence on machine learning models for early sepsis prediction in adult ICU patients from 2017 to 2021, focusing on prediction horizons, data modalities, and validation approaches. A comprehensive search of PubMed, Embase, IEEE Xplore, ACM Digital Library, and arXiv identified studies meeting criteria for ICU-based sepsis prediction with at least a 4-hour forecast window, following PRISMA guidelines. Of 1,478 records screened, 35 studies were included, with prediction horizons ranging from 4 to 24 hours and most relying on hourly vital sign data and internal validation. Reported performance varied widely depending on horizon length, data sampling, and validation rigor, with external validation generally producing lower but more realistic results. Overall, while machine learning models show promising predictive ability, limitations in generalizability and standardization remain, emphasizing the need for stronger validation frameworks and reporting practices to support clinical translation.
Patient no-shows in outpatient clinics (5%–30% across specialties) disrupt scheduling efficiency, increase wait times, and strain healthcare resources. To address this, healthcare systems are increasingly applying machine learning (ML) for predictive scheduling support. This systematic review synthesizes ML approaches for predicting outpatient no-shows, focusing on model types, feature usage, and reported operational deployment outcomes, with emphasis on translation into clinical scheduling practice. A PRISMA-compliant search of PubMed, Embase, IEEE Xplore, Scopus, and Web of Science identified studies using ML for no-show prediction in outpatient settings. Data on models, features, performance, and implementation were extracted. Risk of bias was assessed using an adapted PROBAST tool. Thirty-two studies were included. Logistic regression, random forest, and XGBoost were the most commonly used models. Historical attendance data was the dominant predictive feature. Fewer than 20% of studies reported real-world implementation, and reported intervention outcomes (e.g., overbooking, reminders) were inconsistent. While ML models show strong predictive performance, real-world deployment and evidence of operational impact remain limited. This gap highlights the need to prioritize implementation-focused research to translate predictive accuracy into measurable improvements in clinic efficiency and access.
Hypertension affects about 1.4 billion adults globally and is a major modifiable risk factor for cardiovascular disease. Although several first-line antihypertensive drug classes exist, randomized controlled trials typically report only average treatment effects (ATEs), which mask important variability in individual patient responses. As a result, clinical guidelines often assume a homogeneous patient population, leading to trial-and-error prescribing, delayed blood pressure control, and avoidable adverse effects. I argue that causal forest models combined with double machine learning (DML) enable reliable estimation of heterogeneous treatment effects (HTEs) from observational electronic health record data. These methods can approximate randomized trial validity while capturing clinically meaningful variation in treatment response across patients. Compared with traditional approaches, they are computationally feasible and better suited for individualized treatment assessment. Therefore, comparative effectiveness research in hypertension should move beyond ATE-focused analyses toward routine HTE estimation using causal machine learning. This shift would support more precise, data-driven prescribing and improve patient outcomes.